ArticleThe Journal of antimicrobial chemotherapy2024
Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study.
Article in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Association of elevated linezolid trough concentrations with hyperlactatemia in elderly patients: a multicenter observational study in China.BMC pharmacology & toxicology · 2026Observational
- Population Pharmacokinetics of Linezolid in Elderly Hospitalized Patients: Implications for Therapeutic Drug Monitoring.Pharmaceutics · 2026Article
- Successful Management of Infective Endocarditis Utilizing Rapid High-performance Liquid Chromatography-based Therapeutic Drug Monitoring: Balancing Linezolid Efficacy and Thrombocytopenia Risk.Internal medicine (Tokyo, Japan) · 2026Article
- Optimization of linezolid infusion duration in critically ill patients: a population pharmacokinetic analysis of the trade-off between efficacy and toxicity.Frontiers in pharmacology · 2026Article
- Advances in Therapeutic Drug Monitoring and Pharmacokinetic Researches of Oxazolidinone Antibacterial Agents in the Elderly Patients.Clinical interventions in aging · 2026Review
- Linezolid-associated severe hyperlactatemia masked by metabolic alkalosis in a geriatric patient: a case report.Journal of medical case reports · 2025Article
- Cutaneous nocardiosis in chronic renal insufficiency: Diagnostic and therapeutic considerations.World journal of clinical cases · 2025Article
- Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.Antimicrobial agents and chemotherapy · 2025Article
- Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis.BMC geriatrics · 2025Article
- High accumulation of linezolid and its major metabolite in the serum of patients with hepatic and renal dysfunction is significantly associated with thrombocytopenia and anemia.Microbiology spectrum · 2025Article
- Optimal dosing regimens for linezolid in older patients.Intensive care medicine · 2025Article
- Linezolid Associated Asymptomatic Hypoglycemia in a Patient with Advanced Gynecologic Cancer: A Case Report and Literature Review.International medical case reports journal · 2025Article
- Contezolid for the Super-Elderly: Balancing Efficacy and Safety Through Pharmacokinetic Insights.Clinical interventions in aging · 2025Observational
- LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe concentrations of linezolid, its optimal regimen and the associated side effects in elderly patients remain unclear.
methodsIn this multicentre, prospective study, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and December 2022 were included. Linezolid concentrations and haematological toxicity were monitored dynamically. Risk factors for linezolid overexposure and moderate-to-severe linezolid-induced thrombocytopenia (M/S LIT) were analysed, and a predictive model of M/S LIT was developed.
resultsA total of 860 linezolid concentrations were measured in 313 patients. The median trough concentrations of linezolid were 24.4 (15.3, 35.8) mg/L at 36-72 h and 26.1 (17.0, 38.1) mg/L at 5-10 days (P = 0.132). Severe linezolid exposure was independently associated with age, estimated glomerular filtration rate (eGFR) and the worst SOFA score (SOFA1), and we further recommended dose regimens for elderly patients based on these findings. The incidences of linezolid-induced thrombocytopenia(LIT) and M/S LIT were 73.5% and 47.6%, respectively. M/S LIT was independently correlated with treatment duration, average trough concentration (TDMa), baseline platelet count, eGFR and baseline SOFA score (SOFA0). The developed nomogram predicted M/S LIT with an area under the curve of 0.767 (95% CI 0.715-0.820), a sensitivity of 71.1% and a specificity of 73.2%.
conclusionsLinezolid trough concentrations increased dramatically in the elderly, by about 10 mg/L in patients aged 65-80 years, followed by a further increase of 10 mg/L for every 10 years of age. Therapeutic drug monitoring is recommended in elderly patients receiving linezolid. The developed nomogram may predict M/S LIT and guide dosage adjustments of linezolid. Clinical trial registration number: ChiCTR2100045707.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.